Valneva (VALN) Stock Price, News & Analysis

Company Overview

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners.

Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.

The company continues to develop vaccines for diseases with limited prevention options. Its pipeline has included VLA15, a Lyme disease vaccine candidate being developed with Pfizer, alongside other research and development programs.

Key Stats

• Today's Range: $5.91 to $5.91
• 50-Day Range: $5.26 to $7.12
• 52-Week Range: $4.75 to $12.18
• Volume: 134 shs
• Average Volume: 57,626 shs
• Market Capitalization: $559.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.30
• Consensus Rating: Reduce

Valneva Stock Analysis - MarketRank™

Valneva scored higher than 57% of companies evaluated by MarketBeat, and ranked 505th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Valneva has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Valneva has a consensus price target of $9.30, representing about 57.1% upside from its current price of $5.92.

Amount of Analyst Coverage

Valneva has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Valneva are expected to grow in the coming year, from ($1.27) to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Valneva is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Valneva is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Valneva has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of Valneva has been sold short.

Short Interest Ratio / Days to Cover

Valneva has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Valneva has recently decreased by 75.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Valneva does not currently pay a dividend.

Dividend Growth

Valneva does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.69

News Sentiment

Valneva has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Valneva this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Valneva insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.39% of the stock of Valneva is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/12/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Next Earnings (Estimated): 11/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VALN
• CIK: 1836564
• Web: valneva.com
• Phone: 33-2-28-07-37-10
• Fax: N/A
• Employees: 674
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Valneva: $9.30
• High Price Target: $12.00
• Low Price Target: $4.90
• Potential Upside/Downside: +57.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.45
• P/E Growth: N/A
• Net Income: -$130.33 million
• Net Margins: -110.33%
• Pretax Margin: N/A
• Return on Equity: -153.20%
• Return on Assets: -39.50%

Debt

• Debt-to-Equity Ratio: 2.04
• Current Ratio: 2.16
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: $142.94 million
• Price / Sales: 3.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.39 per share
• Price / Book: 4.26

Miscellaneous

• Outstanding Shares: 95,190,000
• Free Float: 80,997,000
• Market Cap: $563.52 million
• Optionable: Not Optionable
• Beta: 1.37